Cochrane · systematic review · CD012853
Cannabis for the treatment of Crohn's disease
Kafil, TS, Nguyen, TM, MacDonald, JK, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
7
No studies
14
Included studies
NR
No studies 14 · 66.7%Ungraded 0 · 0%Very low 5 · 23.8%Low 2 · 9.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cannabis cigarettes (115 mg THC) compared to placebo cigarettes for the treatment of active Crohn's disease
Population: participants with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of patients achieving clinical remission Cannabis cigarettes (115 mg THC) vs placebo cigarettes | RR 4.55 [0.63, 32.56] | 1 study · 21 participants | Very low Downgraded: risk of bias |
Proportion of patients achieving clinical response Cannabis cigarettes (115 mg THC) vs placebo cigarettes | RR 2.27 [1.04, 4.97] | 1 study · 21 participants | Very low Downgraded: risk of bias |
CRP (mg/dL) at end of study Cannabis cigarettes (115 mg THC) vs placebo cigarettes | RR 1.36 [0.28, 6.56] | 1 study · 21 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Short‐Form 36 health survey (SF‐36) Cannabis cigarettes (115 mg THC) vs placebo cigarettes | no estimate extracted | NR | No studies |
Adverse events Cannabis cigarettes (115 mg THC) vs placebo cigarettes | RR 4.09 [1.15, 14.57] | 1 study · 21 participants | Very low Downgraded: risk of bias |
Serious adverse events Cannabis cigarettes (115 mg THC) vs placebo cigarettes | no estimate extracted | NR | No studies |
Withdrawal due to adverse events Cannabis cigarettes (115 mg THC) vs placebo cigarettes | no estimate extracted | NR | No studies |
Cannabis oil (5% cannabidiol sublingual oil) compared to placebo oil for the treatment of active Crohn's disease
Population: participants with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of patients achieving clinical remission Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil | RR 1.2 [0.36, 3.97] | 1 study · 19 participants | Very low Downgraded: risk of bias |
Proportion of patients achieving clinical response Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil | no estimate extracted | NR | No studies |
CRP (mg/dL) at end of study Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil | no estimate extracted | NR | No studies |
Quality of life Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil | no estimate extracted | NR | No studies |
Adverse events Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil | no estimate extracted | NR | No studies |
Serious adverse events Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil | RR 0.9 [0.07, 12.38] | 1 study · 19 participants | Very low Downgraded: risk of bias |
Withdrawal due to adverse events Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil | no estimate extracted | NR | No studies |
Cannabis oil (15% cannabidiol and 4% THC) compared to placebo oil for the treatment of active Crohn's disease
Population: participants with active Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Proportion of patients achieving clinical remission Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil | no estimate extracted | NR | No studies |
Proportion of patients achieving clinical response Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil | no estimate extracted | NR | No studies |
CRP (mg/dL) at end of study Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil | no estimate extracted | NR | No studies |
Quality of life Short‐Form 36 health survey (SF‐36) Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil | no estimate extracted | 1 study · 39 participants | Low Downgraded: imprecision |
Adverse events Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil | no estimate extracted | NR | No studies |
Serious adverse events Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil | no estimate extracted | NR | No studies |
Withdrawal due to adverse events Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil | no estimate extracted | NR | No studies |